Bill

Bill > A116


NJ A116

NJ A116
Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.


summary

Introduced
01/14/2020
In Committee
01/14/2020
Crossed Over
Passed
Dead
01/11/2022

Introduced Session

2020-2021 Regular Session

Bill Summary

This bill requires a physician to offer to test a patient for dihydropyrimidine dehydrogenase deficiency prior to the patient undergoing chemotherapy. Dihydropyrimidine dehydrogenase deficiency is a disorder in which the human body experiences difficultly or is unable to breakdown chemotherapy drugs leading to a harmful reaction. Under the bill, health insurance plans in this State are to cover expenses incurred in conducting one test for dihydropyrimidine dehydrogenase deficiency every year.

AI Summary

This bill requires a physician to offer to test a patient for dihydropyrimidine dehydrogenase deficiency, a disorder that makes it difficult for the body to break down chemotherapy drugs, before the patient undergoes chemotherapy. The bill also mandates that health insurance plans in New Jersey cover the cost of one such test per year, as well as any necessary prescription drug treatment for the disorder, provided the plan covers prescription drugs.

Committee Categories

Health and Social Services

Sponsors (2)

Last Action

Introduced, Referred to Assembly Health Committee (on 01/14/2020)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...